PL2694075T3 - Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk - Google Patents
Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynkInfo
- Publication number
- PL2694075T3 PL2694075T3 PL12764605.7T PL12764605T PL2694075T3 PL 2694075 T3 PL2694075 T3 PL 2694075T3 PL 12764605 T PL12764605 T PL 12764605T PL 2694075 T3 PL2694075 T3 PL 2694075T3
- Authority
- PL
- Poland
- Prior art keywords
- phosphoinositide
- kinase inhibitor
- binding moiety
- zinc binding
- zinc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470849P | 2011-04-01 | 2011-04-01 | |
| US201161559489P | 2011-11-14 | 2011-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2694075T3 true PL2694075T3 (pl) | 2016-09-30 |
Family
ID=46931927
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16166266T PL3111938T3 (pl) | 2011-04-01 | 2012-03-30 | Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk |
| PL12764605.7T PL2694075T3 (pl) | 2011-04-01 | 2012-03-30 | Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16166266T PL3111938T3 (pl) | 2011-04-01 | 2012-03-30 | Inhibitor 3-kinazy fosfoinozytydowej z grupą wiążącą cynk |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US8710219B2 (pl) |
| EP (2) | EP2694075B1 (pl) |
| JP (3) | JP6242331B2 (pl) |
| KR (2) | KR20180108848A (pl) |
| CN (2) | CN103582483B (pl) |
| AU (1) | AU2012236367B2 (pl) |
| BR (1) | BR112013025340B1 (pl) |
| CA (1) | CA2830822C (pl) |
| CL (1) | CL2013002823A1 (pl) |
| CY (2) | CY1117785T1 (pl) |
| DK (2) | DK3111938T3 (pl) |
| EA (1) | EA022434B9 (pl) |
| ES (2) | ES2577982T3 (pl) |
| HK (1) | HK1194969A1 (pl) |
| HR (2) | HRP20160545T1 (pl) |
| HU (2) | HUE045041T2 (pl) |
| IL (2) | IL228588A (pl) |
| LT (1) | LT3111938T (pl) |
| ME (2) | ME03523B (pl) |
| MX (1) | MX340577B (pl) |
| PE (1) | PE20141382A1 (pl) |
| PL (2) | PL3111938T3 (pl) |
| PT (2) | PT3111938T (pl) |
| RS (2) | RS54903B1 (pl) |
| SG (2) | SG10201602569RA (pl) |
| SI (2) | SI3111938T1 (pl) |
| SM (1) | SMT201600179B (pl) |
| TW (1) | TWI571469B (pl) |
| WO (1) | WO2012135571A1 (pl) |
| ZA (2) | ZA201307082B (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME02230B (me) | 2009-01-08 | 2016-02-20 | Curis Inc | Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink |
| EP2694075B1 (en) | 2011-04-01 | 2016-04-27 | Curis, Inc. | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| UA114900C2 (uk) | 2011-11-14 | 2017-08-28 | Ігніта, Інк. | Похідні урацилу як інгібітори axl і c-met-кінази |
| CN104725301A (zh) * | 2013-12-20 | 2015-06-24 | 北京蓝贝望生物医药科技股份有限公司 | 一种1,2-二氢吡啶-2-酮衍生物的制备方法 |
| KR102015826B1 (ko) | 2015-04-21 | 2019-08-29 | 구이저우 바이링 그룹 파마슈티컬 컴퍼니 리미티드 | 퓨리닐-n-하이드록실 피리미딘 포름아미드 유도체, 이의 제조 방법 및 용도 |
| CA3030660C (en) * | 2016-07-19 | 2023-01-17 | National Institute Of Plant Genome Research | Mutated protein from burkholderia gladioli strain ngj1 against fungal pathogens |
| CA3040727A1 (en) * | 2016-11-02 | 2018-05-11 | Curis, Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| EP3706757A4 (en) * | 2017-11-06 | 2021-08-04 | Cold Spring Harbor Laboratory | PROCESS AND COMPOSITIONS FOR THE MANUFACTURING OF A COPPER-BASED COMPLEX AND THE USE OF IT |
| MX2021002742A (es) | 2018-09-11 | 2021-08-11 | Curis Inc | Terapia combinada con un inhibidor de la fosfoinositida 3-quinasa con un resto de unión a zinc. |
| WO2023212574A1 (en) * | 2022-04-26 | 2023-11-02 | Olivia Szu Hsieh Lee Nakaya | Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5502187A (en) | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
| JP3649395B2 (ja) | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | 縮合ヘテロアリール誘導体 |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| CN101450934B (zh) | 2002-03-13 | 2012-10-10 | 詹森药业有限公司 | 用作组蛋白去乙酰酶抑制剂的磺酰基衍生物 |
| ES2322252T3 (es) | 2002-03-13 | 2009-06-18 | Janssen Pharmaceutica Nv | Aminoderivados como nuevos inhibidores de histona-desacetilasa. |
| CA2476067C (en) | 2002-03-13 | 2011-09-20 | Janssen Pharmaceutica N.V. | Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
| DE60321324D1 (de) | 2002-03-13 | 2008-07-10 | Janssen Pharmaceutica Nv | Sulfonylaminoderivate als neue inhibitoren von histondeacetylase |
| AU2003255845A1 (en) | 2002-08-22 | 2004-03-11 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| CA2514407C (en) | 2003-01-29 | 2012-01-03 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
| EP1745022B1 (en) | 2004-04-05 | 2014-08-13 | Aton Pharma, Inc. | Histone deacetylase inhibitor prodrugs |
| CA2563699C (en) | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
| CA2583259C (en) | 2004-10-08 | 2011-08-02 | Astellas Pharma Inc. | Aromatic ring fused pyrimidine derivative |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| EP1855760A2 (en) | 2005-02-03 | 2007-11-21 | TopoTarget UK Limited | Combination therapies using hdac inhibitors |
| JP5055268B2 (ja) | 2005-05-18 | 2012-10-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼの新規な阻害剤としての置換されたアミノプロペニルピペリジンまたはモルホリン誘導体 |
| EP1979328B1 (en) | 2006-01-19 | 2012-12-26 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| CA2630717C (en) | 2006-01-19 | 2015-02-24 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| ES2376121T3 (es) | 2006-01-19 | 2012-03-09 | Janssen Pharmaceutica, N.V. | Derivados de heterociclilalquilo como nuevos inhibidores de histona deacetilasa. |
| PL2041139T3 (pl) * | 2006-04-26 | 2012-05-31 | Hoffmann La Roche | Związki farmaceutyczne |
| TW200801012A (en) | 2006-04-26 | 2008-01-01 | Piramed Ltd | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| NZ572812A (en) | 2006-04-26 | 2010-09-30 | Hoffmann La Roche | THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR |
| WO2007131364A1 (en) | 2006-05-16 | 2007-11-22 | Mcgill University | Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| JP2010502741A (ja) | 2006-09-11 | 2010-01-28 | キュリス，インコーポレイテッド | Ｐｔｋインヒビターとしての亜鉛結合部分を含む置換２−インドリノン |
| WO2008033745A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety |
| EP2061772A4 (en) | 2006-09-11 | 2011-06-29 | Curis Inc | MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES |
| CN101535279B (zh) | 2006-09-11 | 2015-05-20 | 柯瑞斯公司 | 含锌结合基的喹唑啉基egfr抑制剂 |
| AU2007296743B2 (en) | 2006-09-11 | 2012-02-16 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| SI2343286T1 (sl) | 2006-10-28 | 2015-05-29 | Methylgene Inc. | Derivati dibenzo(b,f)(1,4) oksazepina kot inhibitorji histonske deacetilaze |
| CL2007003520A1 (es) | 2006-12-07 | 2008-08-22 | Piramed Ltd Genentech Inc | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. |
| JP5500990B2 (ja) | 2006-12-07 | 2014-05-21 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法 |
| EP2120900A2 (en) | 2007-02-15 | 2009-11-25 | Novartis AG | Combination of lbh589 with other therapeutic agents for treating cancer |
| CN101674833A (zh) | 2007-03-20 | 2010-03-17 | 柯瑞斯公司 | 含有锌结合半族的Raf激酶抑制剂 |
| TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| WO2009036057A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Antiproliferative agents containing a zinc binding moiety |
| WO2009036020A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Mek inhibitors containing a zinc binding moiety |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| TW200922590A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
| RU2523890C2 (ru) | 2007-09-12 | 2014-07-27 | Дженентек, Инк. | Комбинации ингибиторов фосфоинозитид 3-киназы и химиотерапевтических агентов и способы применения |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| WO2009058895A1 (en) | 2007-10-30 | 2009-05-07 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac and an mtor inhibitor |
| WO2009086012A1 (en) | 2007-12-20 | 2009-07-09 | Curis, Inc. | Aurora inhibitors containing a zinc binding moiety |
| EP2311842A3 (en) | 2008-06-24 | 2011-07-13 | Takeda Pharmaceutical Company Limited | PI3K/M TOR inhibitors |
| WO2009155659A1 (en) | 2008-06-27 | 2009-12-30 | The University Of Queensland | Combination therapy |
| US8196911B2 (en) | 2008-10-27 | 2012-06-12 | Honda Motor Co., Ltd. | Adjustable rate subframe mount |
| ME02230B (me) * | 2009-01-08 | 2016-02-20 | Curis Inc | Inhibitori fosfoinozitid 3-kinaze sa delom koji vezuje cink |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| EP2405916B1 (en) | 2009-03-12 | 2018-02-07 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| CA2776944A1 (en) | 2009-10-12 | 2011-05-12 | F. Hoffmann-La Roche Ag | Combinations of a pi3k inhibitor and a mek inhibitor |
| EP2557923A4 (en) * | 2010-04-16 | 2013-10-23 | Curis Inc | TREATMENT OF CANCER DISORDERS WITH K-RAS MUTATIONS |
| EP2694075B1 (en) * | 2011-04-01 | 2016-04-27 | Curis, Inc. | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| US20130102595A1 (en) | 2011-04-15 | 2013-04-25 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| AU2012290121B2 (en) | 2011-08-01 | 2015-11-26 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors |
| EP4257134A3 (en) | 2015-06-25 | 2024-01-24 | Immunomedics, Inc. | Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| CA3040727A1 (en) * | 2016-11-02 | 2018-05-11 | Curis, Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
-
2012
- 2012-03-30 EP EP12764605.7A patent/EP2694075B1/en active Active
- 2012-03-30 PT PT16166266T patent/PT3111938T/pt unknown
- 2012-03-30 ME MEP-2019-179A patent/ME03523B/me unknown
- 2012-03-30 KR KR1020187026847A patent/KR20180108848A/ko not_active Application Discontinuation
- 2012-03-30 DK DK16166266.3T patent/DK3111938T3/da active
- 2012-03-30 SG SG10201602569RA patent/SG10201602569RA/en unknown
- 2012-03-30 HU HUE16166266A patent/HUE045041T2/hu unknown
- 2012-03-30 WO PCT/US2012/031361 patent/WO2012135571A1/en active Application Filing
- 2012-03-30 MX MX2013011132A patent/MX340577B/es active IP Right Grant
- 2012-03-30 ME MEP-2016-116A patent/ME02451B/me unknown
- 2012-03-30 ES ES12764605.7T patent/ES2577982T3/es active Active
- 2012-03-30 JP JP2014502821A patent/JP6242331B2/ja active Active
- 2012-03-30 PL PL16166266T patent/PL3111938T3/pl unknown
- 2012-03-30 SI SI201231625T patent/SI3111938T1/sl unknown
- 2012-03-30 RS RS20160457A patent/RS54903B1/sr unknown
- 2012-03-30 CA CA2830822A patent/CA2830822C/en active Active
- 2012-03-30 RS RSP20190842 patent/RS59219B1/sr unknown
- 2012-03-30 HU HUE12764605A patent/HUE028910T2/en unknown
- 2012-03-30 SI SI201230597A patent/SI2694075T1/sl unknown
- 2012-03-30 PT PT127646057T patent/PT2694075T/pt unknown
- 2012-03-30 CN CN201280026400.9A patent/CN103582483B/zh active Active
- 2012-03-30 EA EA201301114A patent/EA022434B9/ru unknown
- 2012-03-30 BR BR112013025340-1A patent/BR112013025340B1/pt active IP Right Grant
- 2012-03-30 US US13/435,062 patent/US8710219B2/en active Active
- 2012-03-30 TW TW101111283A patent/TWI571469B/zh active
- 2012-03-30 LT LTEP16166266.3T patent/LT3111938T/lt unknown
- 2012-03-30 DK DK12764605.7T patent/DK2694075T3/en active
- 2012-03-30 AU AU2012236367A patent/AU2012236367B2/en active Active
- 2012-03-30 PL PL12764605.7T patent/PL2694075T3/pl unknown
- 2012-03-30 ES ES16166266T patent/ES2733128T3/es active Active
- 2012-03-30 SG SG2013070883A patent/SG193563A1/en unknown
- 2012-03-30 EP EP16166266.3A patent/EP3111938B1/en active Active
- 2012-03-30 PE PE2013002160A patent/PE20141382A1/es active IP Right Grant
- 2012-03-30 CN CN201610034817.XA patent/CN105461736B/zh active Active
- 2012-03-30 KR KR1020137028748A patent/KR101902325B1/ko active IP Right Grant
-
2013
- 2013-09-19 ZA ZA2013/07082A patent/ZA201307082B/en unknown
- 2013-09-29 IL IL228588A patent/IL228588A/en active IP Right Grant
- 2013-09-30 CL CL2013002823A patent/CL2013002823A1/es unknown
-
2014
- 2014-03-05 US US14/197,769 patent/US9249156B2/en active Active
- 2014-08-11 HK HK14108192.3A patent/HK1194969A1/zh unknown
- 2014-08-21 ZA ZA2014/06167A patent/ZA201406167B/en unknown
-
2015
- 2015-12-28 US US14/979,887 patent/US9657032B2/en active Active
-
2016
- 2016-05-20 HR HRP20160545TT patent/HRP20160545T1/hr unknown
- 2016-06-16 SM SM201600179T patent/SMT201600179B/it unknown
- 2016-07-14 CY CY20161100683T patent/CY1117785T1/el unknown
- 2016-08-08 JP JP2016155625A patent/JP6275784B2/ja active Active
- 2016-10-30 IL IL248597A patent/IL248597B/en active IP Right Grant
-
2017
- 2017-04-25 US US15/496,318 patent/US10111864B2/en active Active
-
2018
- 2018-01-10 JP JP2018001910A patent/JP2018052987A/ja not_active Withdrawn
- 2018-10-03 US US16/150,845 patent/US10543197B2/en active Active
-
2019
- 2019-06-17 HR HRP20191091TT patent/HRP20191091T1/hr unknown
- 2019-07-17 CY CY20191100760T patent/CY1121825T1/el unknown
-
2020
- 2020-01-07 US US16/736,081 patent/US11135205B2/en active Active
-
2021
- 2021-09-09 US US17/470,410 patent/US11654136B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237727A0 (en) | Inhibitors of phosphoinositide 3-kinase with a zinc-binding group | |
| IL248597B (en) | A phosphoinositide-3-kinase inhibitor with a zinc binding site | |
| HK1258842A1 (zh) | 用於檢測活組織上的生物膜的組合物 | |
| ZA201306639B (en) | Attachment mechanism for a contaienr | |
| GB2481513B (en) | A magazine add-on | |
| EP2611352A4 (en) | DISHWASHER | |
| EP2696949A4 (en) | BINDING | |
| GB201002966D0 (en) | A bedchair | |
| GB2484514B (en) | A mechanism | |
| GB201200412D0 (en) | A rake | |
| AU332323S (en) | A bumper guard | |
| AU332267S (en) | A bumper guard | |
| GB201013994D0 (en) | A camrea accessory | |
| GB201116046D0 (en) | A cover | |
| GB201010041D0 (en) | Drawer assembly for a vehicle | |
| GB201116008D0 (en) | A kennel |